Survival and progression-free survival were better with nivolumab alone or with ipilimumab vs ipilimumab alone for stage III or IV melanoma with known BRAFV600 mutation, according to results of this randomized study.
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.
Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.
Immunotherapy alone is not effective in prostate cancer; however, combining it with PD-1/PD-L1 and VISTA inhibitors is effective.
Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).
A small number of patients with cancer treated with immune checkpoint inhibitors may have higher-than-usual risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a case report on 13 patients has shown.
Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
An international study demonstrated that ipilimumab improves the relapse-free survival of patients with advanced stage melanoma who are rendered free of disease surgically but at high risk for relapse.
The adverse event profile of nivolumab with or without ipilimumab in patients with glioblastoma was encouraging.
